Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

EXPAND Clinical Investigators, Guntis Karelis (Member of the Working Group), Andrejs Millers (Member of the Working Group)

Research output: Contribution to journal › Article › peer-review

693 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science

Neuroscience